PCS
NGNE icon

Personal CFO Solutions’s Neurogene NGNE Stock Holding History

Personal CFO Solutions’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-585
Closed -$56K – 502
2021
Q4 		$56K Sell
585
-651
-53% -$79.3K 0.01% 463
2021
Q3 		$179K Buy
1,236
+50
+4% +$7.66K 0.04% 426
2021
Q2 		$219K Buy
1,186
+250
+27% +$55.3K 0.04% 389
2021
Q1 		$230K Hold
936
– – 0.05% 348
2020
Q4 		$264K Buy
+936
New +$229K 0.07% 272

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Personal CFO Solutions's NGNE Position: Q1 2022 in Review

Personal CFO Solutions sold out of Neurogene (NGNE) in Q1 2022, closing a stake of 585 shares — an estimated $56K sold.

Personal CFO Solutions first reported a position in NGNE in Q4 2020 and held it in 5 quarters. The position peaked at $264K in Q4 2020. 81 funds tracked by Wall St. Rank hold NGNE as of Q1 2022.

  • Personal CFO Solutions reported no remaining Neurogene position as of Q1 2022 after selling out during the quarter.
  • Personal CFO Solutions sold 585 Neurogene shares in Q1 2022, an estimated $56K.
  • Personal CFO Solutions first reported a position in Neurogene in Q4 2020 and held it in 5 quarters.
  • Personal CFO Solutions's Neurogene position peaked at $264K in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Neurogene as of Q1 2022.

Based on Personal CFO Solutions's 13F filing for Q1 2022, filed 2 May 2022.